OBJECTIVE：To observe the efficacy and safety of eprosartan in the treatment of hypertensive patients with coronary heart disease. METHODS： 160 hypertensive patients with coronary heart disease randomly divided into observation group and control group. All patients were given aspirin， nitroglycerin， low molecular weight heparin， statins and other conventional treatment； control group was additioanlly given 50 mg Losartan potassium tablet， orally， once a day. Observation group was additionally given 600 mg Eprosartan tablet， orally， once a day. The treatment course for both groups was 6 months. Clinical efficacy， sitting systolic blood pressure and diastolic blood pressure， alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， urea （UREA），creatinine（Cr），uric acid （UA），total cholesterol （TC）， triglyceride （TG）， high-density lipoprotein cholesterol （HDL-C），low-density lipoprotein cholesterol （LDL-C），the Mini-Mental status （MMSE） scale and activities of daily living （ADL） scale scores before and after treatment and incidence of adverse reactions in 2 groups were observed. RESULTS： There was no significant difference in the total effective rate between 2 groups （P＞0.05）. After treatment， the sitting systolic blood pressure and diastolic blood pressure， MMSE and ADL scale scores in 2 groups were significantly lower than before， and sitting systolic blood pressure in observation group was lower than control group， the differences were statistically significant （P＜0.05）， and there were no significant differences in sitting diastolic blood pressure， MMSE and ADL scale scores between 2 groups （P＞0.05）， and no significant differences in ALT， AST， UREA， Cr， UA， TC， TG， HDL-C and LDL-C between 2 groups before and after treatment （P＞0.05）. There were no obvious adverse reactions during treatment. CONCLUSIONS： Eprosartan can effectively reduce sitting systolic blood pressure in hypertensive patients with coronary heart disease， and improve cognitive function， with good safety.